CAR T-Cell Tx Offers Good Outcomes in Refractory NHL – MedPage Today
OncLiveCAR T-Cell Tx Offers Good Outcomes in Refractory NHLMedPage TodayWASHINGTON — The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell, axicabtagene ciloleucel demonstrated significant clinical benefit, and an acceptable safety profile i… Continue reading
